{"id":"https://openalex.org/W2980246735","doi":"https://doi.org/10.1182/blood.v116.21.3389.3389","title":"Effects of Plerixafor (AMD3100) In Combination with Tyrosine Kinase Inhibition In a Murine Model of CML.","display_name":"Effects of Plerixafor (AMD3100) In Combination with Tyrosine Kinase Inhibition In a Murine Model of CML.","publication_year":2010,"publication_date":"2010-11-19","ids":{"openalex":"https://openalex.org/W2980246735","doi":"https://doi.org/10.1182/blood.v116.21.3389.3389","mag":"2980246735"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v116.21.3389.3389","doi":"https://doi.org/10.1182/blood.v116.21.3389.3389","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3389.3389","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076074507","display_name":"Anupriya Agarwal","orcid":"https://orcid.org/0000-0002-8319-6162","observed_orcids":["https://orcid.org/0000-0002-8319-6162"]},"institutions":[{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Anupriya Agarwal","raw_affiliation_strings":["Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,","institution_ids":["https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062406765","display_name":"Angela G. Fleischman","orcid":"https://orcid.org/0000-0002-3701-6079","observed_orcids":["https://orcid.org/0000-0002-3701-6079"]},"institutions":[{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela G. Fleischman","raw_affiliation_strings":["Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,","institution_ids":["https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013204157","display_name":"Curtis Lee Petersen","orcid":"https://orcid.org/0000-0002-7210-447X","observed_orcids":["https://orcid.org/0000-0002-7210-447X"]},"institutions":[{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Curtis L Petersen","raw_affiliation_strings":["Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,","institution_ids":["https://openalex.org/I4390039369"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054155535","display_name":"Marc Loriaux","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc M Loriaux","raw_affiliation_strings":["Department of Pathology, Oregon Health & Science University, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Oregon Health & Science University, Portland, OR, USA","institution_ids":["https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109438902","display_name":"Randy L Woltjer","orcid":"https://orcid.org/0000-0003-0755-9846","observed_orcids":["https://orcid.org/0000-0003-0755-9846"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Randy Woltjer","raw_affiliation_strings":["Department of Pathology, Oregon Health & Science University, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Oregon Health & Science University, Portland, OR, USA","institution_ids":["https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125591963","display_name":"Brian J. Druker","orcid":"https://orcid.org/0000-0001-8331-8206","observed_orcids":["https://orcid.org/0000-0001-8331-8206"]},"institutions":[{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian J Druker","raw_affiliation_strings":["Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,","institution_ids":["https://openalex.org/I4390039369"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007755609","display_name":"Michael W. Deininger","orcid":"https://orcid.org/0000-0002-2987-1331","observed_orcids":["https://orcid.org/0000-0002-2987-1331"]},"institutions":[{"id":"https://openalex.org/I4390039369","display_name":"OHSU Knight Cancer Institute","ror":"https://ror.org/002shna07","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I165690674","https://openalex.org/I4390039369"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael W Deininger","raw_affiliation_strings":["Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, Oregon and Health and Science University Knight Cancer Institute, Portland, OR, USA,","institution_ids":["https://openalex.org/I4390039369"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5013204157","https://openalex.org/A5076074507","https://openalex.org/A5109438902"],"corresponding_institution_ids":["https://openalex.org/I165690674","https://openalex.org/I4390039369"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.5389,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.71826825,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"116","issue":"21","first_page":"3389","last_page":"3389"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11532","display_name":"Chemokine receptors and signaling","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/plerixafor","display_name":"plerixafor","score":0.9769999980926514},{"id":"https://openalex.org/keywords/amd3100","display_name":"AMD3100","score":0.9570000171661377},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9729999899864197},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9570000171661377},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9869999885559082},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":1.0},{"id":"https://openalex.org/keywords/cxcr4","display_name":"CXCR4","score":0.8289999961853027},{"id":"https://openalex.org/keywords/leukemia-stem-cells","display_name":"leukemia stem cells","score":0.9750000238418579},{"id":"https://openalex.org/keywords/bone-marrow-microenvironment","display_name":"bone marrow microenvironment","score":0.8309999704360962},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/disease-persistence","display_name":"disease persistence","score":0.5},{"id":"https://openalex.org/keywords/hematopoietic-stem-cell-mobilization","display_name":"hematopoietic stem cell mobilization","score":0.7480000257492065},{"id":"https://openalex.org/keywords/bcr-abl","display_name":"BCR-ABL","score":0.7059999704360962}],"concepts":[{"id":"https://openalex.org/C2778828106","wikidata":"https://www.wikidata.org/wiki/Q905835","display_name":"Plerixafor","level":5,"score":0.9937212467193604},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.6051089763641357},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.5638058185577393},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5371841192245483},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.5320174694061279},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.5284842252731323},{"id":"https://openalex.org/C129470790","wikidata":"https://www.wikidata.org/wiki/Q415718","display_name":"CXCR4","level":4,"score":0.5279048085212708},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5235583186149597},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.4693739414215088},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.46720239520072937},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.41416677832603455},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3462366461753845},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.3373924493789673},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29196619987487793},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.12616443634033203},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1204485297203064},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.08760955929756165}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v116.21.3389.3389","doi":"https://doi.org/10.1182/blood.v116.21.3389.3389","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3389.3389","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7400000095367432}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1969078983","https://openalex.org/W128716807","https://openalex.org/W2096150843","https://openalex.org/W1863164085","https://openalex.org/W2010593183","https://openalex.org/W39416390","https://openalex.org/W4387542241","https://openalex.org/W2166322995","https://openalex.org/W1978351162","https://openalex.org/W2985654248"],"abstract_inverted_index":{"Abstract":[0,1],"3389":[2],"Background":[3],"Most":[4],"patients":[5,653],"with":[6,12,151,175,222,226,285,395,556,561,654],"chronic":[7],"myeloid":[8,422],"leukemia":[9,26,169,247,583,642],"(CML)":[10],"treated":[11,221,243,388,560],"the":[13,31,106,117,148,182,193,199,293,348,351,372,392,430,436,464,510,521,544,550,623,635],"tyrosine":[14],"kinase":[15,454,468,620],"inhibitor":[16],"(TKI)":[17],"imatinib":[18,40,227,232,264],"attain":[19],"durable":[20],"complete":[21,492],"cytogenetic":[22],"responses.":[23],"However,":[24],"residual":[25,168,330,610],"cells":[27,53,191,291,423,447],"persist":[28],"even":[29],"in":[30,85,165,211,224,258,292,320,371,391,413,424,502,520,543,585,599,638,648],"best":[32],"responders":[33],"and":[34,66,90,109,141,163,241,263,296,301,361,406,427,445,488,490,516,559,603,622,627],"disease":[35,144,209,284,458,611],"recurrence":[36],"usually":[37],"occurs":[38],"when":[39],"is":[41,47,70,82,460],"discontinued.":[42],"The":[43,62,574],"bone":[44,118],"marrow":[45,119,446,558],"niche":[46],"thought":[48],"to":[49,114,116,139,143,203,305,323,435,463,483,509,549,567,578,593],"protect":[50],"leukemic":[51,290,400,541,597],"stem":[52],"(LSC)":[54],"upon":[55,341],"drug":[56],"challenge":[57],"by":[58,187,248],"providing":[59],"survival":[60,137,260,373],"signals.":[61],"interaction":[63,150,184],"between":[64,261,374],"SDF1":[65,87],"its":[67],"receptor":[68],"CXCR4":[69,81,102],"an":[71,321],"important":[72],"mechanism":[73],"that":[74,96,128,449,457,637],"facilitates":[75],"HSC":[76],"homing.":[77],"In":[78,308],"CML":[79,112,214,588],"progenitors":[80],"downregulated,":[83],"resulting":[84],"impaired":[86],"mediated":[88],"migration":[89],"adhesion.":[91],"Recent":[92],"studies":[93,651],"have":[94,661],"shown":[95],"TKI":[97,132,161,204,319],"inhibition":[98,617],"of":[99,131,157,167,173,189,201,246,274,283,287,329,386,397,421,429,466,494,531,536,576,608,618,625,631,652],"BCR-ABL":[100,124,453,467,619],"upregulates":[101],"expression,":[103],"which":[104],"restores":[105],"SDF1/CXCR4":[107,149],"axis":[108],"may":[110,134,159,633],"allow":[111],"LSC":[113,140],"retreat":[115],"niche,":[120],"protecting":[121],"them":[122],"from":[123,443,472,533],"inhibition.":[125,469],"We":[126,195],"hypothesize":[127],"this":[129,586,639],"effect":[130],"therapy":[133],"provide":[135],"a":[136,153,212,309,316,325,534],"signal":[138],"contribute":[142],"persistence.":[145],"Conversely,":[146],"interrupting":[147],"plerixafor,":[152],"small":[154],"molecule":[155],"antagonist":[156],"CXCR4,":[158],"restore":[160],"vulnerability":[162],"result":[164],"elimination":[166],"cells.":[170,401],"Results":[171],"Treatment":[172],"mice":[174,244,389,471,554],"plerixafor":[176,202,223,234,239,503,562,577,632],"(5":[177],"mg/kg":[178,229,335],"daily":[179],"SC)":[180],"disrupted":[181],"CXCR4/SDF1":[183],"as":[185,303,315,433,507,547],"indicated":[186],"mobilization":[188],"CXCR4+":[190],"into":[192,355],"blood.":[194],"then":[196],"tested":[197,313],"if":[198],"addition":[200,575],"(imatinib":[205],"or":[206,236],"dasatinib)":[207],"reduces":[208],"burden":[210,584],"murine":[213,587],"retroviral":[215],"transduction/transplantation":[216],"model.":[217],"Mice":[218],"(10/group)":[219],"were":[220,254,411],"combination":[225,262,375,431,522,545,650],"(100":[228],"BID":[230,336],"orally),":[231],"alone,":[233,235],"carrier.":[237],"All":[238],"alone":[240],"mock":[242],"died":[245],"day":[249],"16":[250],"post":[251,345],"transplant.":[252],"There":[253],"no":[255,368],"significant":[256,369],"differences":[257],"median":[259],"only":[265,359,378,438,512],"groups":[266,271,379,415,474],"(30":[267],"days).":[268,384,527],"Although":[269,402],"both":[270,414,473],"achieved":[272],"normalization":[273],"white":[275],"blood":[276,295],"counts":[277],"(WBC)":[278],"there":[279],"was":[280,339,353,451,498,612],"continued":[281],"evidence":[282],"persistence":[286,396,459],"60\u201380%":[288,398],"GFP+":[289,399],"peripheral":[294],"4":[297],"fold":[298],"larger":[299],"spleens":[300],"livers":[302,426],"compared":[304,434,508,548],"normal":[306,393,412],"mice.":[307],"second":[310],"experiment":[311],"we":[312],"dasatinib":[314,358,377,437,450,511,551,564],"more":[317,326,500,539],"potent":[318],"attempt":[322],"obtain":[324],"faithful":[327],"model":[328,589,640],"disease.":[331],"Dasatinib":[332],"treatment":[333],"(10":[334],"orally,":[337],"N=36)":[338],"initiated":[340],"engraftment":[342],"(day":[343],"12":[344],"transplant).":[346],"Once":[347],"WBC":[349,385],"normalized":[350],"cohort":[352],"divided":[354],"2":[356],"groups:":[357],"(N=19)":[360],"plerixafor+dasatinib":[362],"(N=17).":[363],"Kaplan":[364],"Meier":[365],"analysis":[366,417,530],"showed":[367,418],"difference":[370],"vs":[376,382,525],"(median":[380],"70":[381],"71":[383],"all":[387],"remained":[390,570],"range":[394],"spleen":[403,444,602],"(0.04\u00b1":[404],"0.01g)":[405],"liver":[407],"weights":[408],"(0.7\u00b1":[409],"0.1g)":[410],"histopathological":[416,529],"increased":[419],"infiltration":[420],"spleens,":[425],"lungs":[428],"group":[432,505,513,523,546],"group.":[439,552],"Immunoblotting":[440],"for":[441,565],"pCrkL":[442],"confirmed":[448],"inhibiting":[452],"activity":[455,621],"suggesting":[456],"not":[461,581,613],"due":[462],"lack":[465,624],"Leukemic":[470],"developed":[475],"neurological":[476],"symptoms":[477,517],"including":[478],"rear":[479],"limb":[480],"paralysis,":[481],"leaning":[482],"one":[484],"side,":[485],"head":[486],"tilting":[487],"twisting,":[489],"eventually":[491],"loss":[493],"motor":[495],"control.":[496],"This":[497],"significantly":[499],"frequent":[501],"+dasatinib":[504],"(92%)":[506],"(21%)":[514],"(p<0.001)":[515],"occurred":[518],"earlier":[519],"(40":[524],"58":[526],"Preliminary":[528],"brain":[532,604],"subset":[535],"animals":[537],"suggests":[538],"extensive":[540],"infiltrates":[542,598],"Control":[553],"transplanted":[555],"untransduced":[557],"and/or":[563],"up":[566],"80":[568],"days":[569],"asymptomatic.":[571],"Conclusions":[572],"1)":[573],"TKIs":[579],"does":[580],"reduce":[582],"2)":[590],"Plerixafor+dasatinib":[591],"appears":[592],"promote":[594],"extra":[595],"medullary":[596],"liver,":[600],"lung,":[601],"3)":[605],"A":[606],"state":[607],"minimal":[609],"achieved,":[614],"despite":[615],"efficient":[616],"efficacy":[626],"potential":[628],"detrimental":[629],"effects":[630],"reflect":[634],"fact":[636],"active":[641,656],"persists.":[643],"Caution":[644],"will":[645],"be":[646],"warranted":[647],"clinical":[649],"highly":[655],"CML.":[657],"***First":[658],"three":[659],"authors":[660],"equal":[662],"contribution.":[663],"Disclosures:":[664],"Deininger:":[665],"Genzyme:":[666],"Research":[667],"Funding;":[668],"Novartis:":[669],"Consultancy;":[670,672],"BMS:":[671],"Ariad:":[673],"Consultancy.":[674]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}